A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415)-Reference-Cited by-同舟云学术

A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415)

Published:2021-11 Issue: Volume:158 Page:63-71
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Maluf Fernando C.,Schutz Fabio A.,Cronemberger Eduardo H.,Luz Murilo de A.,Martins Suelen P.S.,Muniz David Q.B.,Bastos Diogo A.,Cárcano Flavio M.,Smaletz Oren^ORCID,Soares Andrey,Peixoto Fábio A.,Gomes Andrea J.,Cruz Felipe M.,Franke Fabio A.,Herchenhorn Daniel,dos Santos Telma M.,Fabricio Vanessa de C.,Gidekel Rosemarie,Werutsky Gustavo,de Jesus Rafaela G.,Souza Vinicius C.,Fay André P.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference28 articles.

1. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate;Huggins;CA Cancer J Clin,1972

2. Adverse health events following intermittent and continuous androgen deprivation in patients with metastatic prostate cancer;Hershman;JAMA Oncol,2016

3. Quality of life in prostate cancer patients taking androgen deprivation therapy;Dacal;J Am Geriatr Soc,2006

4. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup;Iversen;J Urol,2000

5. A randomised comparison of “Casodex” (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer;Tyrrell;Eur Urol,1998

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibitors of the transactivation domain of androgen receptor as a therapy for prostate cancer;Steroids;2024-10

2. Cardiovascular events among men with prostate cancer treated with androgen receptor signaling inhibitors: a systematic review, meta-analysis, and network meta-analysis;Prostate Cancer and Prostatic Diseases;2024-09-05

3. Surgery with or Without Darolutamide in High-risk and/or Locally Advanced Prostate Cancer: The SUGAR (CCAFU-PR2) Phase 2 Trial Rationale and Protocol;European Urology Oncology;2023-10

4. Global Cancer Drug Development—A Report From the 2022 Accelerating Anticancer Agent Development and Validation Meeting;JCO Global Oncology;2023-09

5. The Association Between [⁶⁸Ga]PSMA PET/CT Response and Biochemical Progression in Patients with High-Risk Prostate Cancer Receiving Neoadjuvant Therapy;Journal of Nuclear Medicine;2023-07-20